Cleveland Biolabs Announces Successful Close of Phase 1 Study of CBL0102
April 16, 2014 at 08:03 AM EDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or ...
